Document Type : Original Article(s)
Authors
- Ahmad Shabanizadeh 1
- Hajar Dahim 2
- Reza Salahshoor 3
- Zahra Taghipour 1
- Mohammad Mohsen Taghavi 1
- Hamidreza Gafarineveh 1
- Bahram Eslami 4
- Zahra Babazadeh 5
- Farangis Fatehi 6
1 Department of Anatomy, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
2 Department of Pathology, Shahid Beheshti Hospital, Isfahan, Iran
3 Department of Anatomy, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
4 Department of Anatomy, Faculty of Nursing, Kashmar University of Medical Sciences, Kashmar, Iran
5 Department of Anatomy, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
6 Department of physiology, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Abstract
Background: Ovarian cancer is the leading cause of death among gynecological cancers. Changes in the methylation of BRCA1 and BRCA2 may be an effective mechanism for breast and ovarian cancer. This study evaluates the protein expression and methylation status of BRCA2 in Iranian patients.Methods: We assessed 60 Mullerian-type ovarian cancers by methylation-specific PCR assays and immunohistochemistry.Results: According to methylation status analysis, there were 7 of 60 (11.66%) methylated cases that had low protein expression.Conclusion: We concluded that changes in the methylation status of BRCA2 cannot be used as an appropriate biomarker to ascertain the development of ovarian cancer.
)